Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jingyi He, Jiaqian Qi, Haohao Han, Xiaoyan Xu, Xueqian Li, Xiaofei Song & Yue Han. (2023) Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Expert Review of Hematology 16:5, pages 377-385.
Read now
Read now
Tuğrul Elverdi, Melis Dila Özer Çerme, Tahacan Aydın & Ahmet Emre Eşkazan. (2021) Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?. Expert Review of Clinical Pharmacology 14:10, pages 1183-1188.
Read now
Read now
Thomas Kissner, Guenter Blaich, Andreas Baumann, Sven Kronenberg, Adam Hey, Andrea Kiessling, Petra M. Schmitt, Wouter Driessen, Chantal Carrez, Daniel Kramer, Jennifer Fretland, Wolfgang F. Richter, Tobias Paehler, Ulrike Hopfer & Benno Rattel. (2021) Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting. mAbs 13:1.
Read now
Read now
Articles from other publishers (30)
Tsutomu Takeuchi. (2023) Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor. Modern Rheumatology 33:6, pages 1059-1067.
Crossref
Crossref
Arundhati Pande, Abhishek Kumar, Harshil Krishnani, Sourya Acharya & Samarth Shukla. (2023) Recent Advances in the Management of Microangiopathic Hemolytic Anemias (MAHA): A Narrative Review. Cureus.
Crossref
Crossref
Thomas J. Esparza, Shiran Su, Caroline M. Francescutti, Elvira Rodionova, Joong Hee Kim & David L. Brody. (2023) Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody. Fluids and Barriers of the CNS 20:1.
Crossref
Crossref
M. Scully, R. Rayment, A. Clark, J. P. Westwood, T. Cranfield, R. Gooding, C. N. Bagot, A. Taylor, V. Sankar, D. Gale, T. Dutt, J. McIntyre & W. Lester. (2023) A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. British Journal of Haematology.
Crossref
Crossref
Mia Djulbegovic, Jiayi Tong, Alice Xu, Joanna Yang, Yong Chen, Adam Cuker & Allyson M. Pishko. (2023) Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Blood Advances 7:10, pages 2132-2142.
Crossref
Crossref
Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato, Saeko Uchida & Yoshiya Tanaka. (2023) Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Research & Therapy 25:1.
Crossref
Crossref
Shannen J. Deconinck, Christoph Nix, Svenja Barth, Eveline Bennek‐Schöpping, Antoine Rauch, An‐Sofie Schelpe, Elien Roose, Hendrik B. Feys, Inge Pareyn, Aline Vandenbulcke, Joshua Muia, Christophe Vandenbriele, Sophie Susen, Bart Meyns, Claudia Tersteeg, Steven Jacobs, Simon F. De Meyer & Karen Vanhoorelbeke. (2022) ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation. Journal of Thrombosis and Haemostasis 20:12, pages 2797-2809.
Crossref
Crossref
Ayoade Adeyemi, Francesca Razakariasa, Alexandra Chiorean & Rui de Passos Sousa. (2022) Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune‐mediated thrombotic thrombocytopenic purpura in the United States. Research and Practice in Thrombosis and Haemostasis 6:6, pages e12802.
Crossref
Crossref
Kathryn Ball, Gerard Bruin, Enrique Escandón, Christoph Funk, Joao N.S. Pereira, Tong-Yuan Yang & Hongbin Yu. (2022) Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper. Drug Metabolism and Disposition 50:6, pages 858-866.
Crossref
Crossref
Mehdi Arbabi-Ghahroudi. (2022) Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments. International Journal of Molecular Sciences 23:9, pages 5009.
Crossref
Crossref
Lucas Kühne, Jessica Kaufeld, Linus A. Völker, Ralph Wendt, Ulf Schönermarck, Holger Hägele, Thomas Osterholt, Dennis A. Eichenauer, Markus Bieringer, Anke von Bergwelt‐Baildon, Michael Fischereder, Veronika Buxhofer‐Ausch, Jan Menne, Paul T. Brinkkoetter & Paul Knöbl. (2022) Alternate‐day dosing of caplacizumab for immune‐mediated thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis 20:4, pages 951-960.
Crossref
Crossref
Martin Bergstrand, Emma Hansson, Bernard Delaey, Filip Callewaert, Rui De Passos Sousa & Maria Laura Sargentini‐Maier. (2021) Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura. The Journal of Clinical Pharmacology 62:3, pages 409-421.
Crossref
Crossref
Erez Berman, Iris Noyman, Mordekhay Medvedovsky, Dana Ekstein & Sara Eyal. (2021) Not your usual drug‐drug interactions: Monoclonal antibody–based therapeutics may interact with antiseizure medications. Epilepsia 63:2, pages 271-289.
Crossref
Crossref
Steven de Maat, Chantal C. Clark, Arjan D. Barendrecht, Simone Smits, Nadine D. van Kleef, Hinde El Otmani, Manon WaningMarc van MoorselMichael Szardenings, Nicolas Delaroque, Kristof VercruysseRolf T. Urbanus, Silvie SebastianPeter J. Lenting, Christoph Hagemeyer, Thomas Renné, Karen Vanhoorelbeke, Claudia Tersteeg & Coen Maas. (2022) Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis. Blood 139:4, pages 597-607.
Crossref
Crossref
Masamitsu Nakayama, Shinichi Goto & Shinya Goto. (2022) Effects of caplacizumab, a specific inhibitor of the A1 domain of von Willebrand factor binding with platelet membrane glycoprotein (GP) Ibα, on the length of platelet pseudopods supporting platelet adhesions on immobilized von Willebrand factor under blood flow condition. Journal of Biorheology 36:2, pages 68-75.
Crossref
Crossref
Benjamin Lisle & Cheryl Bushnell. 2022. Stroke. Stroke
592
603.e6
.
Qizhong Lu, Zongliang Zhang, Hexian Li, Kunhong Zhong, Qin Zhao, Zeng Wang, Zhiguo Wu, Donghui Yang, Shuang Sun, Nian Yang, Meijun Zheng, Qiang Chen, Cheng Long, Wenhao Guo, Hui Yang, Chunlai Nie & Aiping Tong. (2021) Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. Journal of Nanobiotechnology 19:1.
Crossref
Crossref
Arghavan Soleimanizadeh, Heiko Dinter & Katharina Schindowski. (2021) Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration. Antibodies 10:4, pages 47.
Crossref
Crossref
Laura Sánchez-García, Eric Voltà-Durán, Eloi Parladé, Elisa Mazzega, Alejandro Sánchez-Chardi, Naroa Serna, Hèctor López-Laguna, Mara Mitstorfer, Ugutz Unzueta, Esther Vázquez, Antonio Villaverde & Ario de Marco. (2021) Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials. ACS Applied Materials & Interfaces 13:25, pages 29406-29415.
Crossref
Crossref
Gennadii M. Galstyan, Alexei A. Maschan, Elizaveta E. Klebanova & Irina I. Kalinina. (2021) Treatment of thrombotic thrombocytopenic purpura. Terapevticheskii arkhiv 93:6, pages 736-745.
Crossref
Crossref
Salvatore Perrone, Mauro Passucci, Elettra Ortu La Barbera, Marcello Capriata, Antonietta Ferretti, Alessandra Mecozzi, Piera Giovangrossi, Francesco Equitani & Giuseppe Cimino. (2021) Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis 36:3, pages 499-504.
Crossref
Crossref
Katarina D. Kovacevic, Stefan Greisenegger, Agnes Langer, Georg Gelbenegger, Nina Buchtele, Ingrid Pabinger, Karin Petroczi, Shuhao Zhu, James C. Gilbert & Bernd Jilma. (2021) The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. Scientific Reports 11:1.
Crossref
Crossref
Adrien Picod, Agnès Veyradier & Paul Coppo. (2021) Should all patients with immune‐mediated thrombotic thrombocytopenic purpura receive caplacizumab?. Journal of Thrombosis and Haemostasis 19:1, pages 58-67.
Crossref
Crossref
Itzcóatl Gómez Aquino & Ioscani Jiménez del Val. 2021. Cell Culture Engineering and Technology. Cell Culture Engineering and Technology
147
188
.
Xiaojing Chi, Xiuying Liu, Conghui Wang, Xinhui Zhang, Xiang Li, Jianhua Hou, Lili Ren, Qi Jin, Jianwei Wang & Wei Yang. (2020) Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nature Communications 11:1.
Crossref
Crossref
Alyssa L Hollifield, Justin R Arnall & Donald C Moore. (2020) Caplacizumab: an anti–von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. American Journal of Health-System Pharmacy 77:15, pages 1201-1207.
Crossref
Crossref
Katarina D. Kovacevic, Nina Buchtele, Christian Schoergenhofer, Ulla Derhaschnig, Georg Gelbenegger, Christine Brostjan, Shuhao Zhu, James C. Gilbert & Bernd Jilma. (2020) The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin. Scientific Reports 10:1.
Crossref
Crossref
Bastiaan Zwart, William A. E. Parker & Robert F. Storey. (2020) New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of Clinical Medicine 9:7, pages 2059.
Crossref
Crossref
Shuhao Zhu, James C. Gilbert, Paul Hatala, Warren Harvey, Zicai Liang, Shan Gao, Daiwu Kang & Bernd Jilma. (2020) The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer. Journal of Thrombosis and Haemostasis 18:5, pages 1113-1123.
Crossref
Crossref
Li Cao, Qiyu Li, Zhen Tong, Yutong Xing, Keyuan Xu, Jessica Yijia Wang, Wenjing Li, Jianhua Zhao, Liqing Zhao & Zhangyong Hong. (2020) HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7. International Journal of Pharmaceutics 574, pages 118939.
Crossref
Crossref